Indications of Rituximab in autoimmune diseases

Drug Discovery Today: Therapeutic Strategies

Volumn 6, Issue 1, 2009, Pages 13-19

  Sanz, Iñaki ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VACCINATION; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 77949489236     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2009.10.001     Document Type: Review

References (50)

1. Looney R.J. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology 44 (2005) ii13-ii17
2. Dörner T., et al. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun. Rev. 9 (2009) 82-89
3. Taylor R.P., and Lindorfer M.A. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat. Clin. Pract. Rheumatol. 3 (2007) 86-95
4. Martin F., and Chan A.C. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 24 (2006) 467-496
5. Lövgren T., et al. Induction of interferon-a production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50 (2004) 1861-1872
6. Manjarrez-Orduno N., et al. B cells and immunological tolerance. J. Invest. Dermatol. 129 (2009) 278-288
7. Lund F.E. Cytokine-producing B lymphocytes - key regulators of immunity. Curr. Opin. Immunol. 20 (2008) 332-338
8. Edwards J.C.W., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40 (2001) 205-211
9. Ahuja A., et al. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl. Acad. Sci. U. S. A. (2008) 4802-4807
10. Looney R.J., et al. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum. 58 (2008) 5-14
11. Cornec D., et al. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun. Rev. 8 (2009) 515-519
12. Leandro M.J., and Torre Idl. Translational mini-review series on B cell-directed therapies: the pathogenic role of B cells in autoantibody-associated autoimmune diseases - lessons from B cell-depletion therapy. Clin. Exp. Immunol. 157 (2009) 191-197
13. Looney R.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50 (2004) 2580-2589
14. Hauser S.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008) 676-688
15. Smolen J.S., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) 143-150
16. Keystone E.C., et al. Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann. Rheum. Dis. (2008) 216-221
17. Dass S., et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58 (2008) 2993-2999
18. Thurlings R.M., et al. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum. 58 (2008) 3657-3664
19. Keystone E., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 56 (2007) 3896-3908
20. Rogier M., et al. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum. 58 (2008) 3657-3664
21. Smolen J.S., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66 (2007) 143-150
22. Breedveld F., et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J. Clin. Pharmacol. 47 (2007) 1119-1128
23. McFarland H.F. The B cell - old player. New position on the team. N. Engl. J. Med. 358 (2008) 664-665
24. Bar-Or A., et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 63 (2008) 395-400
25. Hauser S.L. Multiple lessons for multiple sclerosis. N. Engl. J. Med. 359 (2008) 1838-1841
26. Hawker K., et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66 (2009) 460-471
27. Keogh K.A., et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52 (2005) 262-268
28. Stasi R., et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 45 (2006) 1432-1436
29. Smith K.G.C., et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum. 54 (2006) 2970-2982
30. Aouba A., et al. Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects. Clin. Rev. Allergy Immunol. 34 (2008) 65-73
31. Jones R.B., et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60 (2009) 2156-2168
32. Aries P.M., et al. Lack of efficacy of Rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. (2005) 853-858
33. Taylor S.R.J., et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 60 (2009) 1540-1547
34. Pero M.M.D., et al. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin. Otolaryngol. 34 (2009) 328-335
35. Seo P., et al. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J. Rheumatol. 35 (2008) 2017-2023
36. O'Neill S.K., et al. Change you can B(cell)eive in: recent progress confirms a critical role for B cells in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 16 (2009) 293-298
37. Smith S.H., and Tedder T.F. Targeting B-cells mitigates autoimmune diabetes in NOD mice: What is plan B?. Diabetes 58 (2009) 1479-1481
38. Xiu Y., et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc{gamma}R effector functions. J. Immunol. 180 (2008) 2863-2875
39. Bouaziz J.-D., et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc. Natl. Acad. Sci. (2007) 20878-20883
40. Hu C.-Y., et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117 (2007) 3857-3867
41. Fiorina P., et al. Targeting CD22 reprograms B cells and reverses autoimmune diabetes. Diabetes (2008) db08-0420
42. Sanz I. Ther conundrum of B cell depletion in SLE. Nat. Rev. Rheumatol. 5 (2009) 304-305
43. Lu T., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients. Arthritis Care Res. 61 (2009) 482-487
44. Ramos-Casals M., et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18 (2009) 767-776
45. Merrill J.T., et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER. ACR (2008) Abstract L12 2008
46. Clatworthy M.R., et al. B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med. 360 (2009) 2683-2685
47. Genovese M.C., et al. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann. Rheum. Dis. (2009) 1894-1897
48. Salliot C., et al. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann. Rheum. Dis. (2008) ard.2007.083188
49. Fleischmann R.M. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Sem. Arthr. Rheum. 38 (2009) 265-280
50. Kamar N., et al. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am. J. Transplant. 9 (2009) 244-245